Aroa publishes interim Myriad registry analysis of 411 patients and 474 defects
AI Summary- Aroa published interim MASTRR Registry results covering Myriad treatment of complex soft tissue defects.
- 0.7% of patients developed deep infections, while 2.9% developed superficial infections.
- MASTRR has more than 550 enrolled patients and approval for 800 across 15 U.S. sites.